1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIA Small Business Interest Areas: Biomarkers, research tools, diagnostics, imaging technologies, and AI/ML methods for early detection and monitoring of Alzheimer's Disease (AD), AD-Related Dementias (ADRD), and Age-Related Cognitive Decline is sponsored by National Institute on Aging (NIA) - NIH. NIA Small Business Interest Areas: Biomarkers, research tools, diagnostics, imaging technologies, and AI/ML methods for early detection and monitoring of Alzheimer's Disease (AD), AD-Related Dementias (ADRD), and Age-Related Cognitive Decline is sponsored by National Institute o…
Get alerted about grants like this
Get emailed when new opportunities from “National Institute on Aging (NIA) - NIH” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Small businesses. NIA encourages SBIR and STTR projects addressing Alzheimer's Disease and Related Dementias (AD/ADRD). Confirm the full requirements in the official notice before applying.
The current listing shows up to $700,000 in Phase I and $3 Million in Phase II for AD/ADRD projects. Up to $500,000 in Phase I and $2.5 Million in Phase II for other projects within NIA mission space. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Applications for NIA Small Business Interest Areas: Biomarkers, research tools, diagnostics, imaging technologies, and AI/ML methods for early detection and monitoring of Alzheimer's Disease (AD), AD-Related Dementias (ADRD), and Age-Related Cognitive Decline are due September 5, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
NIA Small Business Interest Areas: Biomarkers, research tools, diagnostics, imaging technologies, and AI/ML methods for early detection and monitoring of Alzheimer's Disease (AD), AD-Related Dementias (ADRD), and Age-Related Cognitive Decline is funded by National Institute on Aging (NIA) - NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
NIA Small Business Programs (SBIR & STTR) is sponsored by National Institute on Aging (NIA) - NIH. The NIA Small Business Programs (SBIR & STTR) provide non-dilutive funding to small businesses for research and development (R&D) focused on healthy aging innovations, including interventions to prevent or treat Alzheimer's disease (AD) and AD-related dementias (ADRD).
NIA Expanding Research in AD/ADRD (ERA) Summer Research Education Program (R25 Independent Clinical Trial Not Allowed) is sponsored by National Institute on Aging (NIA) - NIH. This R25 program from NIA supports a summer research education program aimed at expanding research in Alzheimer's Disease and Related Dementias. It focuses on providing research education experiences for a minimum of 8 to a maximum of 14 weeks each year.
Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15) is sponsored by National Institute on Aging (NIA) - NIH. This program supports small-scale research grants with an emphasis on providing biomedical research experiences primarily for health professional and graduate students, and enhancing the research environment at applicant institutions.
This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D). Funding Opportunity Number: RFA-DK-15-024. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL. Award Amount: $2M total program funding.
This initiative will stimulate and support innovative research by small business concerns that may lead to the development of novel technologies for the early diagnosis, monitoring and treatment of micro and macro vascular complications of diabetes which are associated with significant morbidity and mortality of the disease and high costs to the health care system. Funding Opportunity Number: PA-14-058. Assistance Listing: 93.847. Funding Instrument: G. Category: FN,HL.
NIH has awarded 74% fewer new grants than its 2021-2024 average and is roughly $1 billion behind its normal timeline, but the FY2026 money still has to go out the door before the fiscal year ends. Here is why a year-end obligation cliff is coming, who is positioned to catch it, and how applicants should prepare for a compressed Q4 award rush.
Read articleNew NIH awards have fallen 34% in 2026, NSF is running months behind, and a proposed OMB rule would let political appointees terminate grants mid-stream. The funding environment for academic research has structurally changed. Here is a clear-eyed diversification strategy for PIs, research offices, and institutions that cannot wait for the political fight to resolve.
Read articleOMB's proposed rewrite of 2 CFR Part 200 would bar political appointees from deferring to peer reviewers and require senior-appointee sign-off on every discretionary grant. NIH new awards are already down about 34% in 2026. Here is what the merit-review changes actually say, how 'Gold Standard Science' becomes a scoring lever, why R1 universities are being written out of some solicitations, and what principal investigators and research offices should do before October 1.
Read article